Method for preparing human factor h
AssigneeLaboratoire Francais Du Fractionnement Et Des Biotechnologies
InventorToufik Abache
Life of this patent
Estimating the term…
Abstract
A human cell line for implementing a method for preparing recombinant human factor H, more particularly the recombinant human factor H represented by the sequence SEQ ID NO: 1, or a variant possessing a percentage homology of at least 99% with the sequence SEQ ID NO: 1, with a yield greater than the quantity of endogenous factor H produced by said cell line.
Claims32
A method for preparing recombinant human factor H with a yield greater than the quantity of endogenous factor H produced by a cell line, comprising:
- culturing said cell line transformed by a vector comprising a nucleic acid encoding for the precursor of human factor H.
A human cell line producing endogenous factor H for implementing a method for preparing recombinant human factor H, represented by the sequence SEQ ID NO:
- 1, or a variant possessing a percentage homology of at least 99% with the sequence SEQ ID NO:
- 1, with a yield greater than the quantity of endogenous factor H produced by said cell line.
Nucleic acid encoding for recombinant human factor H having the sequence SEQ ID NO:
- 1, comprising a nucleic acid represented by:
- (i) the sequence SEQ ID NO:
- 2,
- (ii) a sequence having at least 75%, preferably at least 85%, in particular 90%, particularly 95% of sequence identity with sequence SEQ ID NO:
- 2.
Human cells, in particular transformed, producing recombinant human factor H with a yield greater than the quantity of endogenous factor H produced by said cells.
Method for preparing recombinant human factor H, represented by the sequence SEQ ID NO:
- 1, in a human cell line with a yield greater than the quantity of endogenous factor H produced by said cell line, said method comprising the step of:
- (i) culturing said cell line transformed by a vector comprising a nucleic acid encoding for the precursor of human factor H.
Recombinant factor H, characterized in that it has a purity greater than 90%, preferably greater than 95%.
Dependencies are inferred from the claim text.